πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 14,889 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12269801

Modified amino acids

Sutro Biopharma, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268753

Nanomaterials comprising a biodegradable feature

Beam Therapeutics Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269887

Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same,

Regents of the University of Minnesota Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12270814

Kits and methods for prediction and treatment of preeclampsia

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268688

Compositions and methods of use for modified release minoxidil

Veradermics Incorporated Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268777

Compositions and methods for treating eosinophilic disorders

The Regents of the University of California Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268695

Betulin-containing birch bark extracts and their formulation

Amryt Pharmaceuticals Designated Activity Company Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268660

Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension

Aardvark Therapeutics, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268749

Cell-penetrating peptides

United Kingdom Research and Innovation Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268678

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

The Regents of the University of California Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268730

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268737

Stabilized influenza hemagglutinin stem region trimers and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268694

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268693

Pharmaceutical compositions comprising a tolfenamic acid

AXSOME THERAPEUTICS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268683

Compounds and methods for synergistic activation of M channels

The Regents of the University of California Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268720

Bacteriophage for treatment and prevention of E. coli and B. fragilis infections

Armata Pharmaceuticals, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268673

Anhydrous compositions of mTOR inhibitors and methods of use

PALVELLA THERAPEUTICS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264187

Compositions and methods for targeted therapeutic delivery to bone

Theradaptive, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264158

Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing

HEPAREGENIX GMBH Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263180

Method for treatment of COVID-19-associated conditions

Rigel Pharmaceuticals, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264149

Indazole compounds as kinase inhibitors

TYRA BIOSCIENCES, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12264345

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263179

Lyme disease-associated T cell receptor-related methods

Adaptive Biotechnologies Corporation Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted